Americas Technology: Semiconductors: SEMICON West 2026 - Remain bullish on group as industry visibility continues to extend

James Schneider, Ph.D.
+1(212)357-2929 | jim.schneider@gs.com
Goldman Sachs & Co. LLC

Marshall Wong
+1(646)446-0222 | marshall.wong@gs.com
Goldman Sachs & Co. LLC

Liana Wadhwani
+1(212)357-3204 | liana.wadhwani@gs.com
Goldman Sachs & Co. LLC

Anmol Makkar
+1(212)357-1366 | anmol.makkar@gs.com
Goldman Sachs & Co. LLC

Khalil Fenina
+1(212)357-6392 | khalil.fenina@gs.com
Goldman Sachs & Co. LLC

Luya You
+1(212)902-5297 | luya.you@gs.com
Goldman Sachs & Co. LLC

We attended the SEMICON West Conference in San Francisco, California on October 13-14 and met with Applied Materials, Lam Research, Teradyne, Camtek, Onto Innovation, MKS Instruments, and a variety of other companies across the industry. Overall, we came away from the event with an incrementally positive view on WFE growth for 2027 and 2028 - consistent with our recent WFE outlook. **We highlight key industry takeaways, along with company-specific takeaways below:**

WFE trends: Although companies avoided giving quantitative updates on WFE expectations, there was agreement that 2027 is set to be a very strong year, supported by 8-10 new wafer fab openings globally across a variety of product types. Our current estimates call for 2027 WFE to grow ~45% Y/Y to ~$218 bn, driven by DRAM, leading-edge foundry/logic, and NAND.

Leading-edge logic: As AI datacenter buildouts continue to scale, leading-edge logic is positioned to continue growing robustly into next year. We expect leading-edge foundry to underpin this growth rate as we forecast TSMC's CapEx to be $85 bn in 2026 - and we also see the opportunity for incremental growth to be driven by customers such as Intel and Terafab.

DRAM: We expect DRAM spending momentum to continue given increased competition in HBM and a growing need for more CapEx-intensive solutions with more required wafer capacity expansions. We expect Applied and Lam to benefit from continued industry tightness as they are over-indexed to memory. Our checks suggest memory makers continue to prioritize DRAM supply additions over NAND.

NAND: We believe supplier utilization rates remain near peak levels, and expect NAND WFE to accelerate in 2027. However, this spending remains almost entirely driven by upgrades rather than greenfield capacity expansion, which we would not expect to begin until late 2027 at the earliest.

Test: Given increasing levels of chip complexity, innovative solutions are necessary to shorten time to market for customers. However, test times continue to move higher for the latest generations of GPUs and accelerators, which we see as a significant driver of ATE growth over the next few years - along with new markets such as optical networking.

Back-end inspection and metrology: Industry participants remain very constructive on the demand outlook heading into 2027, driven by a number of factors including CoWoS, HBM, and the early ramp of longer-term demand drivers.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

Key Takeaways from Company Meetings

Key Takeaways from Applied Materials Meeting

Participants: Kevin Moraes, VP, Strategy and Marketing; Sree Kesapragada, VP, Advanced Packaging; Mike Sullivan, Head of Investor Relations

Investor questions mainly focused on clarifications tied to the company's investor event and financial targets. On revenue and capital intensity, management noted that semiconductor industry pricing is a key variable that it cannot control - but has high confidence in its framework tied to increasing WFE intensity per node - and these increases have already been programmatically locked in by customers today. On Applied's target of 200bps of market share gain, management noted the complex set of mix effects involved in the calculation, but noted the substantial impact from China export control exclusions. Relative to the company's newly articulated gross margin target of 54% by 2030, Applied believes there is the potential for upside to this target - but pointed out that the vast majority of its costs are variable in nature. On its optical tool portfolio, Applied believes that it can leverage its expertise and market position in e-beam technology to expand into this adjacent $9bn market. On AGS, management has high confidence in its outlook for mid-teens long term revenue growth - but noted that its services attach rate is higher on its newer tools relative to its installed fleet.

Key Takeaways from Lam Research Meeting

Participants: Ram Ganesh - VP of Investor Relations

Consistent with prior commentary, Lam expects 8-10 new fab projects to come online in 2027 - and currently expects product growth to be driven by DRAM, followed by advanced foundry/logic, followed by NAND flash. The company has not specified a timeframe for achieving its new long-term gross margin target of ~55%. However, we expect this to be achieved over several years, and see it tied more to product mix (particularly with new products such as Akara) and overseas operational manufacturing efficiencies rather than like-for-like pricing. Management remains constructive on the company's competitive positioning in Logic, DRAM, and advanced packaging - particularly as etch and deposition intensity continues to grow with a variety of new device structures coming into the mix - including hard masks, surface prep, TSVs, and other materials engineering steps.

Key Takeaways from Teradyne Meeting

Participants: Roy Chorev - VP & GM of Compute Test Division; Amy McAndrews - VP of Investor Relations

Teradyne announced a strategic partnership with and investment in FormFactor at SEMICON West. Teradyne remains committed to an open ecosystem of probe card vendors, but believes Form's strong position in silicon photonics warrants a closer relationship that enables Teradyne to commit additional engineering platform resources. Regarding its XPU business, Teradyne continues to expect to gain merchant GPU share in the long run - and noted that Rubin test times are nearly 2X Blackwell given the near doubling in transistor count. Teradyne is also pursuing the tester opportunity at Intel, which is focused on increasing its exposure to external vendors (currently using an

internal solution) beginning with its foundry business, where Teradyne sees a medium-term opportunity. In its memory business, Teradyne expects minimal impact from customer de-specing of HBM as its demand is tied primarily to unit volume rather than stack height. In co-packaged optics, Teradyne continues to see a very strong product ramp opportunity, although given the early stages of development, there are likely to be significant shifts between testing intensity at different insertions during the manufacturing process.

Key Takeaways from Camtek Investor Meeting

Participants: Lior Aviram - Executive Chairman; Rafi Amit - CEO; Ramy Langer - President & COO; Moshe Eisenberg - CFO; Eyal Segev - Marketing Director

We attended Camtek's Investor Meeting at SEMICON. Our key takeaways are as follows:

- **Long-term financial targets:** In conjunction with its investor meeting, Camtek pre-announced 3Q26 revenue of $160 mn –$161 mn (above its prior guidance), guided to ~$180 mn for 4Q26, and provided an initial 2027 revenue outlook of $800 mn based on orders received to date. Management laid out a long-term revenue target of $1.2 billion in about three years, with a gross margin target of 55%-56% and operating margin target of 34%-36%.
- **Advanced packaging remains the key growth driver:** Camtek stressed that advanced packaging remains its core business, accounting for ~80% of recent orders, and expects advanced packaging wafer growth to run at about twice the broader industry rate through 2031 (13% vs. 7% CAGR). Within advanced packaging, the company expects the high-end of the market (which accounts for the vast majority of its business) to grow at a ~24% CAGR through 2031, driven by AI, silicon photonics, denser interconnects, and increasingly complex inspection and metrology requirements.
- **Technology and product roadmap centered on inspection and specialized metrology:** Camtek's roadmap remains centered on its margin-accretive Hawk and Eagle products for inspection (~85% of its 2026 mix), as well as its metrology platforms. Separately, management also noted it is embedding AI into detection and classification and plans to launch AI-enabled software in 2027 (which it attributed to its Visual Layer acquisition).
- **M&A strategy focused on capability acquisition and strategic expansion:** Camtek noted that it is pursuing both smaller acquisitions that add technology and/or talent to its core business, as well as larger strategic transactions that broaden its offering, while emphasizing that its $1.2 bn revenue target and financial model do not assume meaningful M&A activity.

Key Takeaways from Onto Innovation Meeting

Participants: Brian Roberts - CFO; Sidney Ho - VP of Investor Relations

Onto remains very constructive on the demand outlook through 2H26 and heading into 2027 across a range of demand drivers - with growth likely to accelerate next year given the growth of incremental market opportunities. In HBM, Onto believes its business is likely to be minimally impacted by any "de-spec" activity by XPU vendors, as its tool

demand is far more driven by unit volume than stack height. The company continues to see CoWoS as a key demand driver that is increasingly driven by OSAT partners rather than TSMC; Onto sees EMIB-T as a significant opportunity that promises to be material in 2028. From a competitive standpoint, Onto remains highly confident in its market share position, including at TSMC - and sees no imminent impact from potential product launches by competitors. On margins, management remains confident in its target of 350bps of gross margin expansion, which it believes can be achieved solely by product mix and efficiencies in its manufacturing operations. The company believes it has room to grow revenue substantially from projected levels, and does not see itself as capacity constrained.

Key Takeaways from MKS Instruments Meeting
Participants: John Lee - President & CEO; Paretosh Misra - VP of Investor Relations

MKS believes the industry is in the early-to-middle stages of a substantial cyclical industry upturn driven by AI and datacenter demand. The company is currently preparing for a potential WFE spending envelope of up to $300bn in 2028, and potentially higher over time. In the near-term, management expects the company to potentially outgrow its customers (2Q26 was the first time the company delivered Y/Y Semiconductor revenue growth in excess of them) given supply chain inventory effects. MKS believes it has enough capacity to support WFE of ~$250bn with its Penang facility (with a surge capacity of another 20%), but may need to expand capacity further if these forecasts come to fruition. Importantly, the company does not believe it is constraining its customers' growth plans today. MKS has not taken significant pricing actions, but could do so selectively in order to capture the value it delivers. Management believes its product portfolio is well positioned, but would consider a possible divestiture of its specialty industrial product lines at an attractive valuation.



Valuation/Risks

AMAT (Buy, on CL): Our 12-month price target of $670 is based on a 32X P/E multiple applied to our normalized EPS estimate of $21.00. Key downside risks include: (1) incremental export restrictions; (2) local China-based supplier share gains.

LRCX (Buy): Our price target is $380, which is based on a 35X multiple applied to our normalized EPS forecast of $10.75. Key downside risks: (1) softer DRAM/HBM demand; (2) delays in planned clean room and fab expansions; (3) lower-than-expected content gains from advanced packaging and 3D architectures.

TER (Buy): Our 12-month price target is $465, which is based on a 37X P/E multiple applied to our normalized EPS forecast of $12.50. Key downside risks: (1) delays in the revenue ramp with a merchant GPU customer, (2) significant quarterly volatility due to the lumpy nature of large AI-related infrastructure projects, (3) slower-than-expected recovery in Mobile.

ONTO (Buy): Our12-month price target is $400, which is based on 32X our normalized EPS estimate of $12.50. Our target P/E is in line with peer multiples, and it is on the higher end of ONTO's historical median, given recent momentum around HPC. Key upside/downside risks: (1) additional volume purchase agreements and accelerated customer adoption of Dragonfly G5; (2) shift towards OSATs or domestic Chinese manufacturers; (3) competitor launching a rival tool.

CAMT (Neutral): Our 12-m price target of $160 is based on a 38X P/E multiple applied to our normalized EPS of $4.20. Key upside/downside risks: (1) notable push-outs in chiplet architectures; (2) failure to pass on higher pricing; (3) better-than-expected growth in HPC-driven revenue in the medium-term.

MKSI (Sell): Our 12-month price target is $270, which is based on a 20X P/E multiple applied to our normalized EPS of $13.50. Key upside risks: (1) rebound in the NAND market from an equipment ordering perspective; (2) greater realization of synergies from the Atotech acquisition; (3) any material pickup in momentum for the company's Semiconductor business due to broader WFE trends.



Disclosure Appendix

Reg AC

We, James Schneider, Ph.D., Marshall Wong, Liana Wadhwani, Anmol Makkar, Khalil Fenina and Luya You, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

Contributing Authors: James Schneider, Ph.D. Goldman Sachs & Co. LLC, Marshall Wong Goldman Sachs & Co. LLC, Liana Wadhwani Goldman Sachs & Co. LLC, Anmol Makkar Goldman Sachs & Co. LLC, Khalil Fenina Goldman Sachs & Co. LLC, Luya You Goldman Sachs & Co. LLC.

Unless otherwise stated, the individuals listed in the Contributing Authors disclosure of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

Rating and pricing information

Applied Materials Inc. (Buy, $464.24), Camtek (Neutral, $142.78), Lam Research Corp. (Buy, $301.11), MKS Instruments Inc. (Sell, $247.56), Onto Innovation (Buy, $263.55) and Teradyne Inc. (Buy, $380.29)

The rating(s) for Applied Materials Inc., Camtek, Lam Research Corp., MKS Instruments Inc., Onto Innovation and Teradyne Inc. is/are relative to the other companies in its/their coverage universe: ARM Holdings, Accenture Plc, Advanced Micro Devices Inc., Amkor Technology Inc., Analog Devices Inc., Applied Materials Inc., Broadcom Inc., Cadence Design Systems Inc., Camtek, Cognizant Technology Solutions, Credo Technology Group, EPAM Systems Inc., Entegris Inc., GlobalFoundries Inc., Globant SA, Intel Corp., International Business Machines Corp., KLA Corp., Lam Research Corp., MKS Instruments Inc., Marvell Technology Inc., Microchip Technology Inc., Micron Technology Inc., NXP Semiconductors NV, Nvidia Corp., ON Semiconductor Corp., Onto Innovation, Qnity, Qualcomm Inc., SanDisk Corp., Seagate Technology, SiTime Corp., Synopsys Inc., TaskUs Inc., Teradyne Inc., Texas Instruments Inc., Western Digital Corp.

Company-specific regulatory disclosures

Compendium report: please see disclosures at https://www.gs.com/research/hedge.html. Disclosures applicable to the companies included in this compendium can be found in the latest relevant published research

Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

	Rating Distribution			Investment Banking Relationships		
	Buy	Hold	Sell	Buy	Hold	Sell
Global	50%	34%	16%	65%	58%	43%

As of October 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,094 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Price target and rating history chart(s)

Compendium report: please see disclosures at https://www.gs.com/research/hedge.html. Disclosures applicable to the companies included in this compendium can be found in the latest relevant published research

Target price history table(s)

MKS Instruments Inc. (MKSI)

Date of report	Target price ($)	Closing price ($)
06-Aug-26	270.00	291.31
07-May-26	265.00	300.79
18-Feb-26	200.00	250.36
06-Nov-25	135.00	155.25
08-Oct-25	125.00	132.97
07-Aug-25	92.00	98.77
10-Jul-25	90.00	107.00
13-Feb-25	129.00	103.84
10-Jan-25	128.00	109.07
08-Nov-24	143.00	116.29
03-Sep-24	129.00	107.44

Camtek (CAMT)

Date of report	Target price ($)	Closing price ($)
12-May-26	160.00	174.63
18-Feb-26	145.00	157.54
09-Jan-26	141.00	131.67
15-Dec-25	123.00	109.35

Teradyne Inc. (TER)

Date of report	Target price ($)	Closing price ($)
05-Jul-26	465.00	369.09
30-Apr-26	350.00	343.47
03-Feb-26	300.00	282.98
15-Dec-25	230.00	194.70
29-Oct-25	148.00	173.94
08-Oct-25	130.00	144.60
30-Jul-25	85.00	107.65
10-Jul-25	80.00	98.62
30-Jan-25	140.00	115.08
26-Jul-24	151.00	126.46
20-May-24	161.00	139.51
26-Apr-24	118.00	114.13
01-Feb-24	107.00	95.14
26-Oct-23	103.00	85.12

Onto Innovation (ONTO)

Date of report	Target price ($)	Closing price ($)
17-Aug-26	400.00	351.16

Applied Materials Inc. (AMAT)

Date of report	Target price ($)	Closing price ($)
13-Aug-26	670.00	534.54
05-Jul-26	645.00	603.04
15-May-26	520.00	436.62
13-Feb-26	390.00	354.91
09-Jan-26	310.00	301.18
08-Oct-25	250.00	217.51
15-Aug-25	215.00	161.76
10-Jul-25	225.00	198.03
10-Jan-25	202.00	171.65
15-Nov-24	230.00	168.88
02-Oct-24	228.00	201.15
17-May-24	240.00	212.08
16-Feb-24	220.00	199.57
17-Nov-23	156.00	148.59

Lam Research Corp. (LRCX)

Date of report	Target price ($)	Closing price ($)
05-Jul-26	380.00	351.41
23-Apr-26	290.00	258.56
29-Jan-26	262.00	248.17
09-Jan-26	180.00	218.36
08-Oct-25	160.00	142.54
10-Jul-25	115.00	101.06
30-Jan-25	90.00	80.73
10-Jan-25	85.00	74.65
24-Oct-24	96.00	76.57
02-Oct-24	1,025.00	81.41
01-Aug-24	1,050.00	83.03
25-Apr-24	960.00	90.15
25-Jan-24	912.00	86.56
19-Oct-23	700.00	60.20

Price targets shown in table(s) are unadjusted for corporate actions.

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; registered market maker. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with a subject company, public appearances and trading in securities covered by the analysts.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at https://www.gs.com/worldwide/brazil/area/gir/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details, a copy of the annual compliance audit report and other relevant information and disclosures can be found at this link: https://www.goldmansachs.com/worldwide/india/research-analyst. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at https://www.gs.com/disclosures/europeanpolicy.html which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, and Investment Management Association of Japan. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at https://www.gs.com/research/hedge.html.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research within the European Economic Area.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (https://www.sipc.org).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, make a market or act as liquidity provider in, and buy or sell, any securities, derivatives, or other financial instruments referred to in this research (including any financial instruments issued by the companies referred to herein), unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at https://www.theocc.com/about/publications/character-risks.jsp and https://www.goldmansachs.com/disclosures/cftc_fcm_disclosures. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global

Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to https://research.gs.com.

Disclosure information is also available at https://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY 10282.

© 2026 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. You may not use, extract, download or retrieve this information, in whole or in part, to train, finetune, adjust, influence the weights or behavior of, or otherwise develop or improve a machine learning or artificial intelligence model or system, or provide or reproduce this information, in whole or in part, as a prompt or input to any such system without the express written consent of Goldman Sachs. Furthermore, you may not bulk download this information, or employ any robot, spider, crawler, scraper, automated agent, or other electronic means to scrape, harvest, extract, or retrieve this information, without the express written consent of Goldman Sachs. A breach of the above terms may result in termination of your right to access this service.